Screener / SEC EDGAR /CIK 0001676725 /10-K filed Feb 17, 2026, compared with Feb 18, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

IDEAYA Biosciences, Inc. IDYA

Compare with peers Embed
FY2025 at a glance

Sales up 3024.4%, free cash flow up to -$73.5M

XBRL, from each 10-K
RevenueStatements
$218.7M from $7.0M in FY2024
FY2017FY2025
Net incomeStatements
-$113.7M from -$274.5M in FY2024
FY2017FY2025
Free cash flowStatements
-$73.5M from -$251.4M in FY2024
FY2017FY2025
EPS (diluted)Statements
$-1.28 from $-3.36 in FY2024
FY2017FY2025
Operating marginStatements
-72.8% from -4671.1% in FY2024
FY2017FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (34)
EPS (ttm)
-4.50
Sales (ttm)
36.5M
Net income (ttm)
-420.0M
Sales growth
n/m
EPS growth
-
Sales Q/Q
-95.1%
Free cash flow
-349.8M
Gross margin
-
Oper. margin
n/m
Net margin
n/m
FCF margin
-957.4%
R&D / sales
143.9%
Dividend
-
Debt/Eq
-
Curr. ratio
9.04
Cash
261.5M
Op. cash flow (ttm)
-347.4M
EBITDA
-156.6M
EBITDA margin
-71.6%
Quick ratio
9.04
FCF after stock pay
-119.6M
Oper. margin low 5y
-4671.1%
Stock pay / sales
21.1%
Shares out.
96.7M
Shares Y/Y
+8.3%
Book / share
11.29
Cash / share
2.70
Sales / share
0.38
Asset turnover
0.03
Days sales out.
0
Sales 3Y CAGR
+62.5%
Sales 5Y CAGR
+62.1%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2019 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 218.7M Net income -113.7M
FY2019 revenue 0 · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-22-010922 FY2019 net income -42.0M · NetIncomeLoss, 0001564590-22-010922 0 FY2019 FY2020 revenue 19.5M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-23-006456 FY2020 net income -34.5M · NetIncomeLoss, 0000950170-23-006456 19.5M FY2020 FY2021 revenue 27.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-24-017093 FY2021 net income -49.8M · NetIncomeLoss, 0000950170-24-017093 27.9M FY2021 FY2022 revenue 50.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-25-022183 FY2022 net income -58.7M · NetIncomeLoss, 0000950170-25-022183 50.9M FY2022 FY2023 revenue 23.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-054533 FY2023 net income -113.0M · NetIncomeLoss, 0001193125-26-054533 23.4M FY2023 FY2024 revenue 7.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-054533 FY2024 net income -274.5M · NetIncomeLoss, 0001193125-26-054533 7.0M FY2024 FY2025 revenue 218.7M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-054533 FY2025 net income -113.7M · NetIncomeLoss, 0001193125-26-054533 218.7M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing.

Growth per share, FY2017 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share +7.6% a year FY2020 $8.02 to FY2025 $11.56, 5 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 -$1.28$11.56-$0.83
Dec 31, 2024 -$3.36$12.97-$3.08
Dec 31, 2023 -$1.96$10.80-$2.04
Dec 31, 2022 -$1.42$8.43-$2.19
Dec 31, 2021 -$1.41$8.55-$1.66
Dec 31, 2020 -$1.40$8.02$2.22
Dec 31, 2019 ---
Dec 31, 2018 ---
Dec 31, 2017 ---

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $666.7M
  • − All liabilities $86.4M
  • = Net current asset value $580.3M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $1.0B
  • = Tangible book value $1.0B
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

IDYA against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Return on equity
-5.2%18.5%
-38.5%130th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
-957.4%145th of 145 · median 10.0%
IDYA and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
IDYA IDEAYA Biosciences, Inc.$36.5M ----38.5%-957.4%-
RXRX Recursion Pharmaceuticals, Inc.$68.2M +26.9%5.0%-697.1%-52.5%-458.0%0.01
OCUL Ocular Therapeutix, Inc$50.4M -18.5%87.3%-648.6%-74.1%-530.0%0.17
ROIV Roivant Sciences Ltd.$41.1M -71.6%--838.2%-8.6%-81.2%-
CRSP CRISPR Therapeutics AG$25.2M -90.6%---27.7%-0.36
CGON CG Oncology, Inc.$6.2M +255%---24.0%-0.00
All 162 companies in the group

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity -11.1% FY2020: -17.4% net income ÷ equity
Net margin -52.0% FY2020: -176.6% profit per $ of sales: -113.7M ÷ 218.7M
Asset turnover 0.20× FY2020: 0.07× sales per $ of assets: 218.7M ÷ 1.1B
Leverage 1.08× FY2020: 1.50× assets per $ of equity: 1.1B ÷ 1.0B

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    -1149.6% vs 6.8%
  • Return on equity below 15%
    -38.5%
  • A profit in 0 of 7 years
Net margin, FY2019 to FY2025: -176.6% to -52.0%

Cash and shareholders

  • Free cash flow positive in 1 of 7 years
    −$73.5M last year
  • Share count up over 5 years
    +257.9%
Free cash flow, FY2019 to FY2025: -40.7M to -73.5M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Remaining performance obligations

Signed, not yet recognized $139.8M revenue under contracts the company has not delivered yet, Sep 30, 2026 · -2.3% on a year earlier

Contract liabilities

Paid in advance $2.2M cash received before delivery, not yet recognized as revenue, Sep 30, 2025
  • Sep 30, 2025 $2.2M
  • Sep 30, 2024 $0
  • Jun 30, 2024 $0
  • Mar 31, 2024 $0
  • Dec 31, 2023 $0
  • Sep 30, 2023 $1.4M
  • Jun 30, 2023 $2.8M
  • Mar 31, 2023 $6.3M

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

IDYA's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 9. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue218.7M
FY2017: -FY2018: -FY2019: 0FY2020: 19.5MFY2021: 27.9MFY2022: 50.9MFY2023: 23.4MFY2024: 7.0MFY2025: 218.7M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Net income-113.7M
FY2017: -11.9MFY2018: -34.3MFY2019: -42.0MFY2020: -34.5MFY2021: -49.8MFY2022: -58.7MFY2023: -113.0MFY2024: -274.5MFY2025: -113.7M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow-73.5M
FY2017: -14.0MFY2018: -29.3MFY2019: -40.7MFY2020: 55.0MFY2021: -58.4MFY2022: -90.6MFY2023: -117.6MFY2024: -251.4MFY2025: -73.5M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow after stock pay-119.6M
FY2017: -14.1MFY2018: -30.3MFY2019: -42.8MFY2020: 51.4MFY2021: -66.7MFY2022: -102.2MFY2023: -136.1MFY2024: -286.2MFY2025: -119.6M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
EPS (diluted)-1.28
FY2017: -17.06FY2018: -35.92FY2019: -3.36FY2020: -1.40FY2021: -1.41FY2022: -1.42FY2023: -1.96FY2024: -3.36FY2025: -1.28 FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Diluted shares88.5M
FY2017: -FY2018: -FY2019: -FY2020: 24.7MFY2021: 35.3MFY2022: 41.4MFY2023: 57.5MFY2024: 81.7MFY2025: 88.5M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Income statement

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue--019.5M27.9M50.9M23.4M7.0M218.7M
R&D12.4M31.7M34.3M39.7M58.2M89.5M129.5M294.7M314.7M
SG&A2.1M4.7M10.0M15.2M20.1M23.9M28.3M39.3M63.3M
Operating income-14.4M-36.4M-44.3M-35.3M-50.3M-62.5M-134.4M-327.0M-159.3M
Interest expense19K99K91K82K71K60K69K25K0
Income tax-00000000
Net income-11.9M-34.3M-42.0M-34.5M-49.8M-58.7M-113.0M-274.5M-113.7M
EPS (diluted)-17.06-35.92-3.36-1.40-1.41-1.42-1.96-3.36-1.28
Diluted shares---24.7M35.3M41.4M57.5M81.7M88.5M
Depreciation & amortization391K886K1.2M1.4M1.7M2.1M2.5M2.4M2.7M
EBITDA-14.0M-35.5M-43.0M-34.0M-48.5M-60.4M-132.0M-324.6M-156.6M
Operating margin----180.9%-179.9%-122.7%-574.9%-4671.1%-72.8%
Net margin----176.6%-178.1%-115.2%-483.0%-3921.1%-52.0%
Revenue growth----+43.0%+82.3%-54.1%-70.1%+3024%

Cash flow

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-12.2M-27.6M-39.3M55.5M-55.8M-87.2M-115.2M-247.6M-71.1M
Capital spending1.8M1.7M1.4M493K2.6M3.4M2.4M3.9M2.4M
Free cash flow-14.0M-29.3M-40.7M55.0M-58.4M-90.6M-117.6M-251.4M-73.5M
Stock-based pay (added back)136K950K2.2M3.6M8.2M11.6M18.5M34.7M46.1M
Free cash flow after stock pay-14.1M-30.3M-42.8M51.4M-66.7M-102.2M-136.1M-286.2M-119.6M
Investing cash flow-8.9M-63.2M2.3M-146.2M-69.7M-33.4M-158.5M-502.6M70.0M
Financing cash flow17.5M105.4M50.6M128.8M145.5M97.2M362.7M677.6M29.8M

Stock-based pay and leases

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)136K950K2.2M3.6M8.2M11.6M18.5M34.7M46.1M
Stock-based pay / revenue---18.5%29.5%22.8%79.1%496.4%21.1%
Operating lease cost----1.7M1.7M1.7M1.9M5.0M
Operating lease cash paid--1.7M1.7M1.9M2.0M2.0M1.7M400K
Right-of-use assets-6.1M5.1M5.2M3.9M2.5M2.2M18.8M22.9M
Operating lease liabilities-8.0M6.8M6.7M5.2M3.5M2.9M19.2M27.9M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/IDYA/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.